Great Point Partners LLC Bio Atla, Inc. Transaction History

Great Point Partners LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$4.38 - $18.78 $3.79 Million - $16.2 Million	-864,300 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$19.0 - $30.95 $385,662 - $628,223	20,298 Added 2.4%	864,300 $17 Million
Q3 2021 Nov 15, 2021	BUY	$29.44 - $43.74 $24.8 Million - $36.9 Million	844,002 New	844,002 $24.8 Million

17.4M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $16.7M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.